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Abstract
Aims: Patients with renal failure develop cardiovascular alterations which contribute to the higher rate of cardiac death.
Blockade of the renin angiotensin system ameliorates the development of such changes. It is unclear, however, to what
extent ACE-inhibitors can also reverse existing cardiovascular alterations. Therefore, we investigated the effect of high dose
enalapril treatment on these alterations.
Methods: Male Sprague Dawley rats underwent subtotal nephrectomy (SNX, n=34) or sham operation (sham, n=39). Eight
weeks after surgery, rats were sacrificed or allocated to treatment with either high-dose enalapril, combination of
furosemide/dihydralazine or solvent for 4 weeks. Heart and aorta were evaluated using morphometry, stereological
techniques and TaqMan PCR.
Results: After 8 and 12 weeks systolic blood pressure, albumin excretion, and left ventricular weight were significantly
higher in untreated SNX compared to sham. Twelve weeks after SNX a significantly higher volume density of cardiac
interstitial tissue (2.5760.43% in SNX vs 1.5060.43% in sham, p,0.05) and a significantly lower capillary length density
(45326355 mm/mm
3 in SNX vs 50236624 mm/mm
3 in sham, p,0.05) were found. Treatment of SNX with enalapril from
week 8–12 significantly improved myocardial fibrosis (1.6360.25%, p,0.05), but not capillary reduction (39086486 mm/
mm
3) or increased intercapillary distance. In contrast, alternative antihypertensive treatment showed no such effect.
Significantly increased media thickness together with decreased vascular smooth muscles cell number and a disarray of
elastic fibres were found in the aorta of SNX animals compared to sham. Both antihypertensive treatments failed to cause
complete regression of these alterations.
Conclusions: The study indicates that high dose ACE-I treatment causes partial, but not complete, reversal of cardiovascular
changes in SNX.
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Introduction
The development of left ventricular hypertrophy (LVH) and
structural abnormalities of the heart and vessels is a key
abnormality in chronic kidney disease (CKD) that potentially
contributes to the high rate of cardiac death in this population [1].
Among the myocardial changes that accompany LVH in
experimental renal failure as well as in patients with CKD the
following play major roles: myocardial fibrosis [2,3], loss of
cardiomyocytes [4], thickening of intramyocardial arterioles [5–6]
and finally marked capillary deficit causing a mismatch between
cardiomyocyte hypertrophy and capillary density [7–8].
Recent clinical and experimental studies document that the
pathogenesis of these cardiovascular abnormalities is complex.
Certainly, these abnormalities are not fully explained by increased
pre- or afterload or by anemia [9–12]. Amongst others, the local
renin aldosteron angiotensin system (RAS) seems to play a decisive
role [1,13]. Other studies documented elevated angiotensin II and
renin mRNA expression in the myocardium of subtotally
nephrectomized animals (SNX) with moderate chronic renal failure
[14,15]. In experimental renal failure blocking the RAS with an
angiotensin converting enzyme (ACE) inhibitor (ACE-I) prevented
development and progression of LVH and associated structural
alterations such as myocardial fibrosis and loss of cardiomyocytes
[16]. In patients with CKD evidence of regression of LVH after
long-term treatment with either ACE-I or combination treatment
was found [17,18]. Regression of LVH was also seen in
hemodialysed patients with a policy of negative sodium balance,
thus lowering blood pressure in the absence of any medication
[19,20]. These studies in human beings could not address the issue
how structural alterations of the heart in CKD were affected by
either ACE-I or blood pressure lowering, respectively.
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prevalent cardiac abnormalities and how these were affected in
detail has not been investigated so far.
These considerations prompted the present study in subtotally
nephrectomized rats which had developed major cardiovascular
pathology. It was particularly designed to investigate the
hypothesis that high-dose treatment with the ACE-I enalapril,
but not treatment with alternative blood pressure lowering drugs
reversed such existing cardiovascular pathology, i.e. LVH,
interstitial myocardial fibrosis, reduced myocardial capillary
supply, intramyocardial arteriolar and aortic wall thickening. In
a standard model of moderate experimental renal failure [21] we
assessed structural changes of the heart and the aorta in untreated
SNX animals at 8 weeks and in addition compared at 12 weeks
untreated SNX with SNX that had been treated for 4 weeks (week
8–12) with high-dose enalapril. To exclude confounding by
lowering of blood pressure we studied in parallel SNX and sham
operated animals treated with the non-specific antihypertensive
combination furosemide and dihydralazine.
Materials and Methods
1. Animals and study design (fig. 1A)
Three months old male Sprague Dawley rats (Charles River Co,
Sulzfeld, Germany), mean body weight 379627 g, were housed at
constant room temperature (21uC) and humidity (75%) and exposed
to a 12 h light on, 12 h light off cycle. The animals had free access to
water and were fed pellets (23.4% protein, 4.5% fat, 6% fiber, 0.4%
sodium;AltrominGmbH,Lage,Germany).Aftera7daysadaptation
period, rats were randomly allotted to subtotal nephrectomy (SNX,
n=34) or sham operation (sham, n=39). As described before [16]
rats were subtotally nephrectomized in two steps: first, the right
kidney was surgically removed and kidney weight was carefully
protocolled, then, one week later weight controlled removal of
cortical tissue of the hypertrophied left kidney corresponding to 2/3
of the weight of the right kidney. This standardized procedure of two-
step, weight controlled surgical resection of renal cortex resulted in a
verymoderate and stable degree ofrenal failurewith a minor increase
in systolic blood pressure, if any. Using the above procedure of
moderate two-step subtotal nephrectomy the total nephron number is
reduced from approximately 60,000 to 15,000.
Eight weeks after the second operation, one group of sham and
SNX animals was sacrified in order to clearly demonstrate the
findings before the onset of therapy (sham 8 wks, SNX 8 wks). The
remaining sham and SNX rats were randomly allotted to 2
treatment arms for another 4 weeks (fig. 1A): (i) enalapril treatment
(E, 48 mg/kg bw per day, sham+E, SNX+E), (ii) furosemide (F) +
dihydralazine (D) treatment (F/D, 15+20 mg/kg bw, sham+F/D,
SNXF/D). One group of sham and SNX animals was left
untreated (sham 12 wks, SNX 12 wks). Treatment was given by
adding the drugs to the drinking water at concentrations
calculated to deliver the above mentioned dose. Daily food and
water consumption were monitored and the doses were adjusted.
The enalapril dose used in the current study exceeds the
antihypertensive dose used in previous prevention studies by a
factor of 4. In previous studies our group had shown that
treatment with the ACE-I ramipril prevented the development of
LVH and myocardial fibrosis in SNX rats [4,16]. When designing
the present study we reasoned that in contrast to prevention [16],
regression of already altered heart morphology might require a
higher dose of E, e.g. 48 mg/kg body weight [22] similar to the
high doses necessary to cause regression of glomerular sclerosis
[23]. In the absence of studies on regression of cardiovascular
alterations we chose the dose used by Ikoma et al. [22] who
showed that in SNX a dose of 48 mg/kg bw enalapril, but not
lower doses caused regression of glomerular lesions. The doses of F
and D were chosen according to a previous study
5 and adjusted to
induce a comparable blood pressure lowering.
Ethics statement. All animal work has been conducted
a c c o r d i n gt or e l e v a n tn a t i o n a la n dinternational guidelines. Formal
approval was given by the local authorities (Regierungspra ¨sidium
Karlsruhe, AZ 35-9185.81/69/98).
2. Blood pressure (bp) and urinary albumin
measurements
Systolic bp and heart rate were measured at weeks 2, 5, 7, 9 and
11 using tail plethysmography in conscious rats that were
acquainted to the measuring conditions. In each animal 6
consecutive measurements per session were performed.
Seven and 11 weeks after SNX animals were placed in
metabolic cages and 24 h urine was collected to measure urine
volume, electrolyte and albumin excretion [24].
3. Tissue preparation, morphometry and stereology
After the above mentioned recordings and blood sampling the
experiment was terminated by retrograde perfusion fixation via the
abdominal aorta Perfusion pressure was adapted according to the in
vivo blood pressure of the animals, i.e. 120–140 mmHg. Perfusion
was started with rheomacrodex/procainhydrochloride in order to
prevent interstitial edema and artifacts due to various states of
vasodilation, followed by either glutaraldehyde for morphometric
and stereological investigations or icecold NaCl for molecular
studies [5]. After the perfusion, the heart of each animal was taken
out and the total heart weight aswell as the left ventricular weight
were determined. From glutaraldehyde fixed hearts tissue samples
and sections were obtained and stained according to the orientator
method (fordetailssee[16,25]).Thus,semithinsectionsof8random
samples of the left ventricular muscle including the septum were cut
and examined by light microscopy with oil immersion and phase
contrast at a magnification of 1:1000. All investigations were
performedina blinded manner,i.e.theobserverwasunawareofthe
study group the animal belonged to. Volume density (VV)o f
capillaries, interstitial tissue and myocytes was obtained using the
point counting method according to the equation PP =V V (with PP
is point density). Reference volume was the total myocardial tissue
(exclusiveof non-capillaryvessels, i.e. arterioles and veins,and tissue
clefts). Vascular geometry of intramyocardial arterioles, i.e. vessels
with lumen diameters between 20 and 120 mm and at least one
muscular layer, was analysed using planimetry and a semiautomatic
image analysis system (Analysis, SIS, Mu ¨nster, Germany) as
described in detail [5,6]. Thereby, mean wall thickness, lumen
diameter, media and lumen area were determined in every arteriole
that was present in all semithin sections per animal.
A 3 mm thick slice of the descending aorta was also embedded
in Epon Araldite and semithin sections were prepared for
quantitative and qualitative evaluation of the aortic wall. The
remaining cardiac and aortic tissue was embedded in paraffin and
3 mm thick sections were prepared and stained with HE and Sirius
red (for visualization and quantification of fibrous tissue).
4. TaqMan PCR for cardiac TGF-b, TIMP-1 and TMP-2 gene
expression
Total RNA was extracted with the Qiagen MiniKit (Qiagen
GmbH, Hilden, Germany). First-strand cDNA was synthesized
with TaqMan reverse transcription reagents (Applied Biosystems,
Darmstadt, Germany) using random hexamers as primers.
Reactions without Multiscribe reverse transcriptase were used as
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performed with a Step One Plus Sequence Detector System
FastSYBR Green Universal PCR Master Mix (Applied Biosys-
tems), as described previously [26]. All samples were run in
triplicate. Specific mRNA levels in hypertensive animals relative to
UNX controls were calculated and normalized to a housekeeping
gene with the D-D-CT method as specified by the manufacturer
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/
documents/generaldocuments/cms_040980.pdf).
Primer pairs and probes for transforming growth factor- b
(TGF-b) [27] and tissue inhibitor of metalloproteases-1 and -2
(TIMP-1) were designed using Primer Express software (Perkin
Elmer, Foster City, CA, USA) [28]. The relative amount of the
specific mRNA was normalized with respect to 18S rRNA. All
samples were run in triplicate.
5. Statistics
All statistical analysis was performed with SPSS 13. Data are
given as mean 6 standard deviation apart from the results of the
TaqMan PCR which are provided as box plots. ANOVA was used
for comparison of means followed by appropriate post-hoc tests. If
distributional assumptions were in doubt the nonparametric
Kruskal-Wallis-test was chosen. The zero-hypothesis was rejected
at p,0.05.
Results
1. Animal data
Enalapril (E) had no effect on body weight, but reversed
left ventricular hypertrophy (LVH) in SNX animals (table 1,
fig. 1B). At the end of the present experiment body weight was
Figure 1. Experimental protocol (A) and left ventricular weight (B). A. Experimental protocol. B. Effect of treatment with the ACE-I enalapril
or furosemide/dihydralazine on left ventricular weight (g). The increase in left ventricular weight (g) in untreated SNX at week 12 is completely
prevented by enalapril, not by furosemide/dihydralazine treatment.
doi:10.1371/journal.pone.0015287.g001
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after SNX the weight of the left ventricle (LVW) was significantly
higher in untreated SNX and SNX+F/D compared to sham
indicating left ventricular hypertrophy (LVH). After 12 weeks
LVW was significantly lower in SNX+E compared to untreated
SNX documenting regression of LVH in SNX animals (fig. 1B). S-
creatinine and urea as well as albuminuria were significantly
higher in all SNX groups compared to sham (table 1). Of note,
neither enalapril (E) nor furosemide/dihydralazine (F/D)
treatment significantly lowered these parameters.
Comparable effects of enalapril (E) and furosemide/
dihydralazine (F/D) on systolic blood pressure (bp)
(fig. 2A). Two weeks after SNX systolic bp was not
significantly different between the groups. From week 5 onward
bp was moderately, but significantly higher in untreated SNX than
in untreated sham. Treatment with E and F/D significantly and
comparably lowered bp in SNX and sham compared to untreated
animals. Of note, at week 7, i.e. 1 week before the initiation of
antihypertensive treatment bp was highest in the SNX+F/D group
and this might have some potential effect on any of the readout
parameters although this remains speculative.
2. Effect of RAS blockade and alternative
antihypertensive treatment on interstitial myocardial
fibrosis and capillarisation in SNX (table 2, figs. 2B,3,4)
Enalapril (E), but not furosemide/dihydralazine (F/D)
treatment caused regression of myocardial fibrosis in SNX
animals (fig. 2B,3). At weeks 8 and 12 volume density of
interstitial tissue (Vv int in %) as an index of myocardial fibrosis
was significantly higher in untreated SNX than in sham operated
rats (fig. 2B,3). Whereas RAS blockade with E significantly
lowered the percentage of myocardial fibrous tissue compared to
the values of untreated SNX at weeks 8 and 12, alternative
antihypertensive treatment with F/D did not show such an effect.
The effect of Enalapril (E) on cardiac fibrosis in SNX
animals was only partly dependent on lowering of TGF-b
and TIMP expression (fig. 4). In the hearts of untreated SNX
at 12 weeks markedly increased TGF-b, TIMP-1 and TIMP-2
mRNA expression compared to control animals was found by
TaqMan PCR (fig. 4). Due to the high standard deviation of
cardiac gene expression the difference was only statistically
significant for TIMP-1 (fig. 4B). Expression of all 3 profibrotic
genes was again markedly lowered by both antihypertensive
treatments, but the differences were not statistically significant
(fig. 4).
Enalapril (E) and furosemide/dihydralazine (F/D)
treatment had no beneficial effect on reduced myocardial
capillary density in SNX (table 2). At 8 weeks after SNX
capillary length density (Lv), i.e. the total length of capillaries per
unit myocardial volume, as a three-dimensional parameter of
myocardial capillary supply was comparable in untreated SNX
and sham animals. After 12 weeks myocardial capillary length
density was markedly lower in untreated SNX compared to sham.
Because of the high standard deviation this marked difference
failed to be statistically significant. Antihypertensive treatment
with either E or F/D did not improve myocardial capillary density
in either SNX or sham animals. In SNX+E animals Lv was even
lower compared to untreated SNX and F/D treatment. Changes
in intercapillary distance, an important parameter of myocardial
blood supply, went in parallel. In addition, myocardial
intercapillary distance was significant higher in SNX 8 weeks
than in sham (table 2).
3. Effect of RAS blockade and alternative
antihypertensive treatment on changes of
intramyocardial arterioles
Treatment with furosemide/dihydralazine (F/D), but not
with Enalapril reversed wall thickening of intramyocardial
Table 1. Animal data: Effect of treatment with enalapril (E) or furosemide/dihydralazine (F/D) from week 8–12 in sham-op and SNX
rats, respectively.
group body weight [g] S-creatinine [mg/dl] S-urea [mg/dl] albuminuria [mg/day]
SHAM 8 wks
n=10
500620 0.4860.08 40.862.9 2.7662.65
SHAM 12 wks
n=10
552624 0.4960.06 44.263.3 4.3864.90
SHAM +E
n=11
538628 0.5360.08 56.1611.8 0.8160.63
SHAM + F/D
n=8
586639 0.460.05 42.465.26 1.3161.34
SNX 8 wks
n=8
486631 0.8560.19 a 86.5613.9 a 1156116 a
SNX 12 wks
n=8
531652 0.8860.23 a 97.9632.1 a 2776148 a
SNX +E
n=11
491625 0.9260.08 a 107619 a 2586220 a
SNX + F/D
n=7
544619 1.0160.57 a 118.1667 a 1926195 a
analysis of variance ns p,0.001 p,0.05 p,0.001
mean 6 standard deviation,
1 weight after perfusion fixation.
a) p,0.05 vs. corresponding SHAM.
b) p,0.05 vs. SNX 8 wks.
c) p,0.05 vs. SNX 12 wks.
d) p,0.05 vs. SNX+E.
doi:10.1371/journal.pone.0015287.t001
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lumen diameters between 15 and 50 mm were measured. The
mean number of intramyocardial arterioles assessed per animal
ranged from 6 to 32. The cumulative frequencies of arteries were
not different between the groups excluding a sampling error. This
conclusion is further supported by the fact that the mean lumen
diameter was not significantly different between untreated sham
and SNX 8 weeks (table 2). Lumen diameter in SNX 12 weeks and
SNX+E was significantly lower than in SNX 8 weeks. In addition,
it was significantly higher in SNX+F/D than in SNX+E. Wall
thickness, wall:lumen ratio and media area (not shown) of
intramyocardial arterioles were significantly higher in SNX 12
Figure 2. Effect of treatment with the ACE-I enalapril or furosemide/dihydralazine on systolic blood pressure (A) and myocardial
interstitial fibrosis (B). A. Enalapril (E) and furosemide/dihydralazine (F/D) treatment lowered systolic blood pressure (bp) in sham and SNX to the
same extent. Two weeks after SNX systolic bp was not significantly different between the groups. From week 5 onward bp was significantly higher
(p,0.01) in untreated SNX than in untreated sham. At week 7 bp was highest in the SNX+F/D group. Treatment with E and F/D significantly and
comparably lowered bp in SNX and sham compared to untreated animals. Mean of systolic blood pressure measurements at weeks 2, 5, 7, 9 and 11
using tail plethysmography in conscious rats that were acquainted to the measuring conditions. *: p,0.01 compared to all other groups. +:p ,0.05
compared to all other groups. B. The increase in myocardial interstitial tissue (%) in untreated SNX at week 12 is completely prevented by enalapril,
but not by furosemide/dihydralazine treatment. *: p,0.05 vs SNX 12 weeks. +:p ,0.05 vs corresponding sham.
doi:10.1371/journal.pone.0015287.g002
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were significantly lower in the SNX+F/D group.
4. Effect of RAS blockade and alternative
antihypertensive treatment on changes of the aortic wall
Enalapril (E), but not furosemide/dihydralazine (F/D)
lowered increased aortic wall thickness in SNX (table 3,
fig. 5). Aortic lumen diameter and lumen area were not
significantly different between untreated sham and untreated
SNX at 8 and 12 weeks. Lumen diameter was significantly lower
in SNX+E compared to sham+E and significantly higher in
SNX+F/D than in SNX 8 weeks presumably indicating vessel
dilatation. In contrast, aortic media thickness at week 8 was
significantly higher in SNX than in sham, whereas at week 12 due
to the somewhat higher standard deviation there was only a
tendency to higher values in SNX. Treatment of SNX with E, but
not with F/D lowered aortic media thickness (table 3).
Enalapril (E) and furosemide/dihydralazine (F/D)
improved aortic VSMC/matrix ratio in SNX animals
(table 3, fig. 5). At weeks 8 and 12 the number of aortic
VSMC per unit media area was significantly lower in untreated
SNX compared to sham (table 3). In parallel, aortic extracellular
matrix content as seen in fibrous tissue stains and semithin sections
(fig. 5) was higher in untreated SNX (fig. 5C) than in sham (fig. 5A)
indicating structural remodelling of the aortic wall. Of note, in
both treated SNX groups (SNX+E, SNX+F/D) the number of
VSMC per aortic media area was significantly increased
compared to untreated SNX (tab. 3), but there was no effect on
elastic fibre content (data not shown).
Discussion
In the present study the effect of 4 weeks of ACE inhibition
(ACE-I) with high-dose enalapril (E) treatment on the regression of
LVH and accompanying abnormalities of myocardium and aorta
were investigated in an experimental modelof chronic renal
failure, i.e. the subtotally nephrectomized rats (SNX). Potential
effects of blood pressure (bp) lowering by E were controlled for by
a treatment arm with comparable bp lowering, i.e. a combination
of furosemide and dihydralazine (F/D). Treatment with E, but not
with F/D led to regression of LVH and myocardial interstitial
fibrosis. In contrast, no beneficial effect of E was seen on reduction
Table 2. Effect of enalapril (E) or furosemide/dihydralazine (F/D) treatment from week 8–12 in sham-op and SNX on
intramyocardial arterioles and capillaries.
group lumen diameter [mm] wall thickness [mm]
wall:lumen ratio [mm/
mm*10
22] Lv [mm/mm
3]
Intercapillary distance
[mm]
SHAM 8 wks
n=10
30.064.9 3.360.5 12.462.7 41396486 16.861.1
SHAM 12 wks
n=10
25.962.7 4.361.0 17.764.7 50236624 15.361.0 b
SHAM +E
n=11
27.966.9 4.862.0 18.8610.4 53396915 14.961.2 b
SHAM + F/D
n=8
33.564.8 2.960.4 10.764.4 46416429 15.760.7
SNX 8 wks
n=8
32.365.4 c,d 4.160.6 c,d 13.964.1 c,d 40866517 16.961.1
SNX 12 wks
n=8
26.962.7 b 5.460.7 b 21.863.2 b 45326355 d 16.060.7 d
SNX +E
n=11
25.264.3 b 5.961.7 a,b 24.768.8 a,b 39086486 a,c 17.361.2 a,c
SNX + F/D
n=7
32.164.4 d 3.760.6 c,d 12.963.2 c,d 46106553 d 15.961.0 d
analysis of variance p,0.05 p,0.05 p,0.05 p,0.05 p,0.05
Mean 6 standard deviation.
a) p,0.05 vs. corresponding SHAM.
b) p,0.05 vs. SNX 8 wks.
c) p,0.05 vs. SNX 12 wks.
d) p,0.05 vs. SNX+E.
doi:10.1371/journal.pone.0015287.t002
Figure 3. Myocardial fibrosis in untreated sham operated
animals (A), sham+enalapril (B), untreated SNX 12 weeks (C)
and SNX + enalapril (D). Note increased myocardial fibrous tissue
content (depicted in red) in untreated SNX at 12 weeks (C) compared to
untreated and treated sham (A,B). Complete regression of interstitial
fibrosis is seen at 12 weeks after 4 weeks treatment with enalapril
(D).Sirius red stain, magnification x 400.
doi:10.1371/journal.pone.0015287.g003
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thickening of intramyocardial arteries in SNX, respectively.
Thickening of the aortic media in SNX was only partly, but not
completely regressed by E treatment. The structural alterations of
aortic media in SNX, i.e. decreased ratio VSMC:extracellular
matrix were positively affected by both antihypertensive treat-
ments.
Some methodological aspects of the present study deserve
further comments:
In our hands the standard model of SNX induces reproducibly
stable moderate chronic renal failure that is accompanied by only
moderately increased systolic bp [5,16]. This is in contrast to
findings in alternative models of renal insufficiency, i.e. the renal
artery ligation model where bp is markedly increased [29]. In the
SNX model by surgical ablation plasma Ang II is decreased,
presumably due to volume overload, while increased local
formation of Ang II has been reported in extrarenal resistance
vessels [30]. The mechanisms contributing to higher local Ang II
levels may include higher levels of the precursor protein
angiotensinogen, and a decreased degradation of Ang II [30].
We are not aware of studies directly addressing such mechanisms
in the heart. However, an upregulation of Ang II AT1 receptors
and increased local renin mRNA in the myocardium has been
reported after subtotal nephrectomy [7,13,31]. Higher AT1
receptor density may lead to a more pronounced local cardiac
effect of Ang II. Of note, in a recent study [32] renal AT1
receptors were found to be required for the development of Ang
II-dependent hypertension and cardiac hypertrophy suggesting
that the major mechanism of action of RAS inhibitors in
hypertension is attenuation of Ang II effects in the kidney.
In previous studies our group had shown that treatment with the
ACE-I ramipril prevented the development of LVH and
myocardial fibrosis in SNX rats [4,16]. When designing the
present study we reasoned that in contrast to prevention [33],
regression of already altered heart morphology might require a
higher dose of E, e.g. 48 mg/kg body weight [22] similar to the
high doses necessary to cause regression of glomerular sclerosis
[23]. In addition, there is accumulating data in the proteinuric
nephropathy setting that using super-high doses of AT1 blockers
can indeed be of added clinical benefit [34]. The combination of
furosemide and dihydralazine was used to achieve comparable bp
control; previous studies in this laboratory had documented that
this combination did not affect morphological changes of the heart
in SNX [5]. This is also in line with our past observation that the
development of LVH in SNX is bp independent [4,10,11] since it
cannot be prevented by bp lowering with either calcium channel
blockers or other bp lowering agents, but only with ACE-I,
endothelin receptor blockade or sympatholytic agents. These
observations point so some pathogenetic involvement of these and
other systems like for example increased PTH [1–3].
As already mentioned [32] Ang II was shown to affect
hypertension and subsequent heart hypertrophy through its AT1
receptors in the kidney. In the absence of hypertension (due to the
renal knockout of AT1), cardial AT1 receptors were not sufficient
to cause hypertrophy. At first glance, these findings appear to
conflict with the notion that the effects of RAS blockade were
Figure 4. Effect of treatment with the ACE-I enalapril or furosemide/dihydralazine on cardiac mRNA expression of TGF-b (A), TIMP-1
(B) and TIMP-2 (B). Increased TGF-b mRNA expression in untreated SNX was lowered by both antihypertensive treatments. Cardiac TIMP-1 gene
expression was also significantly higher in untreated SNX 12 weeks than in sham and SNX 8 weeks; RAS blockade by ACE-I and alternative
antihypertensive treatment both lowered cardiac TIMP-1 gene expression in SNX animals. The same tendency was seen for TIMP-2 mRNA expression.
The data are provided as box plots of the DCT analysis. u indicate outlyers.
doi:10.1371/journal.pone.0015287.g004
Table 3. Effect of enalapril (E) or furosemide/dihydralazine (F/D) treatment from week 8–12 in sham-op and SNX on the aortic wall.
group lumen diameter [mm] lumen area [mm
2] media thickness [mm] media area [mm
2]
number of VSMC per
media area [1/mm
2]
SHAM 8 wks
n=10
11776375 1.1960.71 88.968.9 0.42260.17 19.267.07
SHAM 12 wks
n=10
14876464 1.8960.85 97.6611.7 0.65860.25 18.462.60
SHAM +E
n=11
11096395 1.0860.78 83.267.32 0.43160.12 18.362.27
SHAM + F/D
n=8
18096294 2.6360.77 100611.9 0.70560.21 20.462.94
SNX 8 wks
n=8
13126383 1.4560.82 10566.47 a 0.58260.20 14.462.53 a
SNX 12 wks
n=8
16766298 2.2760.81 109621.9 0.79260.30 10.862.36 a.d
SNX + E
n=11
14716270 a 1.7560.59 98.6618.4 a 0.63460.21 a 14.862.00 a.c
SNX + F/D
n=7
18546530 b 2.8961.26 b.d 109619.7 0.85960.25 b.d 15.462.22 a.c
analysis of variance p,0.05 p,0.05 p,0.05 p,0.05 p,0.05
Mean 6 standard deviation.
a) p,0.05 vs. corresponding SHAM.
b) p,0.05 vs. SNX 8 wks.
c) p,0.05 vs. SNX 12 wks.
d) p,0.05 vs. SNX+E.
doi:10.1371/journal.pone.0015287.t003
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the experimental setup were different. Apart from species
differences and different strategies to interfere with the RAS,
kidney AT1 receptors were not knocked out in our model but
some degree of Ang II signaling through AT1 was certainly
present in the kidney. Further, the effects of local RAS activation
on the heart may be more pronounced in the presence of volume
overload which could occur in subtotal nephrectomy. We have to
acknowledge, however, that some of the effects of F/D treatment
can be presumably explained by differences in bp before the start
of treatment and particulary by increased natriuresis which has
been shown to help to prevent and regress LVH [19,20].
There is good evidence for a role of the local cardiac RAS (and
possibly bradykinin) in the pathogenesis of myocardial fibrosis
[35]. Gonzalez et al. [36] showed that AngII signalling via the AT-
1 receptor, MAPK/ERK and SMAD stimulates procollagen I
formation and inhibits the activity of collagenases resulting in
increased collagen I accumulation. This cascade is further
modulated by TGF-b, PDGF, aldosterone, integrins and PAI-1
[36]. Of note, in the present experimental study TGF-b, TIMP-1
and TIMP-2 mRNA expression was not specifically altered by E
treatment (and this was also confirmed for TGF-b on the protein
level using immunohistochemistry, data not shown). In experi-
mental renal failure as well, ACE-I therapy attenuated the
development of myocardial fibrosis and cardiomyocyte hypertro-
phy as a result of activating lysosomal proteinases [37]. In past
experiments we treated SNX animals with a combination of ACE-
I and bradykinin antagonist; thereby the bradykinin antagonist
abrogated the beneficial effect of ACE-I [35]. In addition to
inhibiting cardiac fibrosis, ACE-I also reduced the loss of
cardiomyocytes by apoptosis in SNX rats [4].
Apart from activation of the local RAS in the heart, changed
elasticity of central arteries, mainly the aorta, also contribute to the
development of LVH in CKD. This was documented by London
et al in CKD patients [38]. Reduced aortic elasticity increases the
pressure load imposed upon the left ventricle thus aggravating
LVH. It is therefore of note that in the present study we confirmed
reduced elastic fibre content and disturbed architecture of elastic
fibres in the aorta of SNX animals [5,16]. This will increase aortic
stiffness together with the observed reduced VSMC numbers and
increased extracellular matrix. Of note, on a qualitative base these
structural alterations were positively affected by high-dose ACE-I.
This is in line with data on a protective effect of ramipril in animal
models of hypertension without renal dysfunction [39].
Our previous studies had documented a selective and marked
increase of myocardial interstitial non-vascular tissue in SNX rats
[3] and in uremic patients [40]. In uremic patients myocardial
fibrosis was shown to be independent of potential confounders
such as hypertension, diabetes or duration of dialysis [41]. In SNX
animals treatment with the ACE-I ramipril, but not with the
sympatholytic agent moxonidine or the calcium channel blocker
nifedipine prevented the development of myocardial fibrosis [4].
This finding is confirmed and extended by the results of the
present study: Enalapril, but not alternative antihypertensive
treatment with furosemide/dihydralazine caused even regression
of established myocardial fibrosis. Regression is proven by the
observation that at week 12 the interstitial tissue area of SNX
animals which had received high dose E for 4 weeks was even
lower than the baseline value in untreated SNX at week 8. Apart
from lowering of AngII by ACE-I a complementary explanation
might be accumulation of bradykinin and we had already provided
evidence for this in an earlier study using the SNX model [35].
Minshall et al. [42] documented bradykinin-2-receptors on
neonatal and adult rat fibroblasts as well as cardiomyocytes.
Stimulation of these receptors influences proliferation and protein
synthesis directly and indirectly (via nitric oxide or prostacyclin) in
various tissues [43]. It is therefore conceivable that bradykinin
accumulation in the myocardium inhibits collagen synthesis by
interstitial fibroblasts [44]. This idea is in line with increased
PCNA positivity of interstitial cells indicating activation of
fibroblasts and increased TGF-b expression in the heart of SNX
animals compared to sham operated controls [10]. Of note, in
renal failure PTH has a permissive role on the activation of
interstitial fibroblasts in vitro and in vitro [3]. Ultrastructural
analysis in SNX animals 14 days after subtotal nephrectomy
documented early selective activation of cardiac interstitial
fibroblasts, but not of endothelial cells [2]. Furthermore, Suzuki
et al. documented that the increase in interstitial matrix is due to
both increased production by activated fibroblasts and decreased
matrix removal by MMPs [37].
The length density of intramyocardial capillaries as a three-
dimensional parameter of myocardial capillary supply is signifi-
cantly reduced in experimental renal failure
8 as well as in uremic
patients [40]. Reduced myocardial capillary supply increases the
intercapillary distance thus lowering pO2 midways between the
capillaries thus rendering the myocardium more susceptible for
ischemic injury [8,10]. Deficient capillary supply is a feature of
LVH in renal failure. Its development is independent of bp [16].
In SNX reduced myocardial capillary supply is prevented by
selective blockade of the sympathetic and endothelin systems
[16,45] as well as by the antioxidant vitamin E [46] but not by
ACE-I [16]. The present study extends the latter finding by
documenting that low capillary density is not reversed by E either;
we noted even a tendency to lower values after E treatment. This
finding could be due to a blockade of the promitogenic effect of
Ang II on endothelial cells [47] by ACE-I. An alternative
explantation may be exhaustion of the endothelial cell pool after
intense endothelial cell/mesenchymal transition [48]. As expected
based on the findings of the various prevention studies treatment
with F/D did not show any beneficial effect on reduced
myocardial capillary density.
Thickening of intramyocardial arterioles as well as of extra-
cardiac arteries and veins is found in SNX rats and in CKD
patients [5,10,16]. In the present study we noted only a tendency
Figure 5. Effect of treatment with the ACE-I enalapril (E) on
aortic wall thickness and aortic remodelling in sham (A,B) and
SNX rats (C,D). The increase in aortic wall thickness in untreated SNX
(C) compared to untreated and E-treated sham (A,B) reversed by
antihypertensive treatment with enalapril (D).
doi:10.1371/journal.pone.0015287.g005
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animals which increased with the duration of renal failure and was
significant at 12 weeks. This increase in wall thickness was not
regressed or prevented by E which is in line with previous studies
of our group [5,16], but contrasts to data of Kakinuma et al [49]
who described a protective effect of ACE-I with respect to vascular
thickening in experimental renal failure. The marked effect of F/D
on intramyocaridal arteriolar wall thickness and wall: lumen ratio
was unexpected. F/D treatment had also an effect on the arteriolar
diameter which is increased possibly indicating arteriolar dilata-
tion.
In summary, in subtotally nephrectomized rats, high doses of
the ACE-I enalapril cause regression of LVH and interstitial
myocardial fibrosis. In addition, regression of abnormal aortic wall
texture is observed. These results of this short term study extend
previous experimental findings that lower doses of ACE-I prevent
cardiac and aortic pathology and provide another argument for
the clinical use of ACE-I in patients with CKD and established
cardiovascular pathology. In remarkable contrast, myocardial
capillary density and intercapillary distance, crucial determinants
of tissue hypoxia tolerance, were not positively affected by ACE-I
treatment. It remains to be investigated, however, whether longer
treatment periods or addition of combination treatment with AT2
or aldosterone receptor blockers or renin inhibition, respectively,
may increase the effects.
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